Fertility Preservation in Female Cancer Patients: A Retrospective Study from Iran
Introduction: Improvements in cancer treatments have improved survival, thus it is important to improve the quality of life of cancer survivors. Use of fertility preservation methods has developed considerably in recent years. Therefore, in order to save future fertility, consultation with cancer patients is important.
Patients and Methods: This was a retrospective cohort study among female patients with different cancer disorders who were referred to IVF center, Taleghani Hospital, in Iran between April 2014 and September 2014 for fertility preservation.
Results: Eighteen patients were referred, with a mean age of 27 years, 9 patients (50%) before gonadotoxic treatment and 9 patients (50%) after previous gonadotoxic treatment. The mean value of anti-mullerian hormone was 1.6 ng/ml, and the mean antral follicle count per ovary was 4. For 14 patients (77.8%), embryo cryopreservation and for 4 others (22.2%) oocyte cryopreservation was carried out. Patients with a history of gonadotoxic therapy needed more gonadotropins for stimulation (4328 IU versus 2233 IU, P<0.05). Patients with lower antral follicle count had lower oocytes (p<0.05) and patients with lower anti mullerian hormone had lower antral follicle count per ovary (p<0.05).
Conclusion: Due to the high dose of gonadotropins for stimulation and its effect on anti mullerian hormone and antral follicle count, in patients with a history of gonadotoxic therapy, it is recommended that patients be referred for fertility preservation before gonadotoxic treatment.